Market Research Logo

Hemophilia Gene Therapy Market - Size, Share, Trends, and Forecast to 2026

Hemophilia Gene Therapy Market - Size, Share, Trends, and Forecast to 2026

Hemophilia is a genetic disorder in which patient’s blood do not clot normally due to lack of blood-clotting proteins known as coagulating factors. Conventional treatment options include timely replacement of the specific clotting factor. Major pharma and biotech companies are conducting research and development to develop gene therapy for hemophilia due to various shortcomings with conventional therapy. Increasing number of hemophilic patients that require treatment and strong product pipeline are expected to drive growth of the hemophilia gene therapy market.

Market Dynamics

Major factors that are driving growth of the hemophilia gene therapy market include increasing prevalence of hemophilia, issue of high cost, access to current hemophilia treatment, which includes coagulation factor VIII and IX, and increasing number of companies engaged in research and development of gene therapy products. According to the Centers for Disease Control and Prevention, hemophilia A is a rare, X-linked bleeding disorder that affects around 1 in 5,000 to 10,000 live-born males. Hemophilia B is less common than hemophilia A, with an incidence of around 1 in 25,000 births. According to 2016 global survey by the World Federation of Hemophilia, the total number of individuals with hemophilia worldwide was 184,723, including 16,949 within the U.S.

Key features of the study:

  • This report provides in-depth analysis of the global hemophilia gene therapy market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, pipeline analysis, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global hemophilia gene therapy market based on the following parameters – company overview, financial performance, market presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include BioMarin Pharmaceuticals, Inc., Spark Therapeutics, Pfizer, Inc., UniQure NV, Ultragenyx Pharmaceutical, Shire PLC, Sangamo Therapeutics, Inc., and Freeline Therapeutics
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, product up-gradation, market expansion, and marketing tactics
  • The global hemophilia gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the hemophilia gene therapy market
Detailed Segmentation:
  • Global Hemophilia Gene Therapy Market, By Type:
  • Hemophilia A
  • Hemophilia B
  • Global Hemophilia Gene Therapy Market, By Region:
  • North America
  • By Type
  • Hemophilia A
  • Hemophilia B
  • By Country:
  • U.S.
  • Canada
  • Latin America
  • By Type
  • Hemophilia A
  • Hemophilia B
  • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • By Type
  • Hemophilia A
  • Hemophilia B
  • By Country:
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Type
  • Hemophilia A
  • Hemophilia B
  • By Country:
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • By Type
  • Hemophilia A
  • Hemophilia B
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Type
  • Hemophilia A
  • Hemophilia B
  • By Country:
  • South Africa
  • Central Africa
  • North Africa
  • Company Profiles
  • BioMarin Pharmaceuticals, Inc. *
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategies
  • Spark Therapeutics
  • Pfizer, Inc.
  • UniQure NV
  • Ultragenyx Pharmaceutical
  • Shire PLC
  • Sangamo Therapeutics
  • Freeline Therapeutics
“*” marked represents similar segmentation in other categories in the respective section.


1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Hemophilia Type
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Pipeline Analysis
Primary Research Respondents View About Market
Mergers, Acquisitions, and Collaborations
Regulatory Scenario
PEST Analysis
Epidemiological Data
4. Global Hemophilia Gene Therapy Market, By Product Type, 2018 – 2026, (US$ Mn)
Introduction
Market Share Analysis, 2017 and 2025 (%)
Y-o-Y Growth Analysis, 2017 – 2026
Segment Trends
Hemophilia A
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Hemophilia B
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
5. Global Hemophilia Gene Therapy Market, By Region, 2018 – 2026, (US$ Mn)
Introduction
Market Share Analysis, By Region, 2017 and 2026 (%)
Y-o-Y Growth Analysis, For Regions, 2017 – 2026
North America
Market Size and Forecast, By Hemophilia Type, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
U.S.
Canada
Latin America
Market Size and Forecast, By Hemophilia Type, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Market Size and Forecast, By Hemophilia Type, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
Market Size and Forecast, By Hemophilia Type, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Market Size and Forecast, By Hemophilia Type, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
Market Size and Forecast, By Hemophilia Type, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
South Africa
Central Africa
North Africa
6. Competitive Landscape
Market Share Analysis
Company Profiles
BioMarin Pharmaceuticals, Inc.*
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
Spark Therapeutics
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
Pfizer, Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
UniQure NV
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
Ultragenyx Pharmaceutical
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
Shire PLC
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
Sangamo Therapeutics, Inc
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
Freeline Therapeutics
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
Analyst Views
7. Section
References
Research Methodology
About us and Sales Contact
*Browse 16 market data tables and 21 figures on "Hemophilia Gene Therapy Market - Global forecast to 2026”.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report